Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
TECH - Bio-Techne Corp
Market Cap 12.91B P/E 48.82 EPS this Y 6.80% Ern Qtrly Grth -46.20%
Income 168.07M Forward P/E 34.17 EPS next Y 15.30% 50D Avg Chg 1.00%
Sales 1.16B PEG 3.68 EPS past 5Y 11.95% 200D Avg Chg 3.00%
Dividend N/A Price/Book 6.83 EPS next 5Y 11.25% 52W High Chg -16.00%
Recommedations 1.90 Quick Ratio 2.47 Shares Outstanding 158.65M 52W Low Chg 21.00%
Insider Own 1.02% ROA 5.74% Shares Float 156.82M Beta 1.27
Inst Own 100.17% ROE 8.33% Shares Shorted/Prior 3.70M/2.95M Price 82.02
Gross Margin 66.47% Profit Margin 14.50% Avg. Volume 914,012 Target Price 83.32
Oper. Margin 22.44% Earnings Date Oct 29 Volume 1,280,237 Change -0.10%
Healthcare | Biotechnology | United States
About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp News
11/20/24 BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES
11/18/24 BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
11/14/24 BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO
11/11/24 UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
11/11/24 BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
11/08/24 BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES
11/07/24 ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy
11/06/24 There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
11/06/24 BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING
11/06/24 Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH)
11/05/24 LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH
10/31/24 Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges in a ...
10/31/24 Q1 2025 Bio-Techne Corp Earnings Call
10/30/24 Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket
10/30/24 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
10/30/24 BIO-TECHNE DECLARES DIVIDEND
10/29/24 What to Expect From These 3 MedTech Stocks This Earnings Season
10/29/24 ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics
10/21/24 Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards?
10/10/24 Calculating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)
TECH Chatroom

User Image Estimize Posted - 2 weeks ago

Wall St is expecting 0.39 EPS for $TECH Q2 [Reporting 02/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

User Image IN0V8 Posted - 10/31/24

$TECH Scotiabank raises target price to $88 from $83 Stifel raises target price to $75 from $65

User Image RallyRaider Posted - 10/30/24

$TECH see the pattern starting at April 24....... they often do this----- beat it down then make it go on manipulated consensus

User Image OpenOutcrier Posted - 10/30/24

$TECH (+4.7% pre) BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS https://finance.yahoo.com/news/bio-techne-releases-first-quarter-103000393.html

User Image DonCorleone77 Posted - 10/30/24

$TECH Bio-Techne reports Q1 adjusted EPS 42c, consensus 38c Reports Q1 revenue $289.46M, consensus $280.26M. "The start to fiscal 2025 was largely consistent with our expectations, as a high-level of execution by the Bio-Techne team drove continued momentum across our Diagnostics & Spatial Biology segment," said Kim Kelderman, president and CEO of Bio-Techne. "This was augmented by strong results in our cell and gene therapy business, including robust growth in our GMP reagent portfolio. The strength in cell and gene therapy, combined with favorable year-to-date funding dynamics, gives us increased confidence in the forthcoming recovery in our biotech end market."

User Image RallyRaider Posted - 10/29/24

$TECH long ahead of earnings tomorrow morning

User Image Estimize Posted - 10/28/24

Wall St is expecting -6.92% YoY EPS growth for $TECH in Q1, up from -10.91% in Q4 [Reporting 10/30 BMO] http://www.estimize.com/intro/tech?

User Image TradingAlerts65 Posted - 4 weeks ago

$MHK $CFG $TECH $EPAM $TYL https://youtu.be/T--FVfRtdG4

User Image TradingAlerts65 Posted - 1 month ago

$TECH $EPAM $TYL https://youtu.be/yZKqaGiahU0

User Image swingingtech Posted - 1 month ago

$XLV $MOH $TECH $BDX https://wallstreetwaves.com/unexpected-12-month-price-forecast-for-xlv-by-analyst/

User Image neofeudal Posted - 1 month ago

Buying. $TECH

User Image vjtweet Posted - 09/26/24

$TECH if it can hold above 78 tomorrow...

User Image Stock_Titan Posted - 09/26/24

$TECH LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH https://www.stocktitan.net/news/TECH/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-tlmmmlusru3j.html

User Image Stock_Titan Posted - 2 months ago

$TECH ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape https://www.stocktitan.net/news/TECH/scale-ready-announces-a-g-rex-r-grant-has-been-awarded-to-immuno-14z5v2glbtpi.html

User Image Stock_Titan Posted - 2 months ago

$TECH Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant https://www.stocktitan.net/news/TECH/verismo-therapeutics-awarded-a-scale-ready-g-rex-r-r69d1xwn8n8s.html

User Image Stock_Titan Posted - 2 months ago

$TECH ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics https://www.stocktitan.net/news/TECH/scale-ready-announces-a-g-rex-r-grant-has-been-awarded-to-verismo-5fydd92sfxcn.html

User Image Stock_Titan Posted - 2 months ago

$TECH ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies https://www.stocktitan.net/news/TECH/scale-ready-and-bio-techne-announce-optimal-closed-system-cytokine-y9jc2xsafgvn.html

User Image IN0V8 Posted - 2 months ago

$TECH Stephens cuts target price to $85 from $90

User Image Stock_Titan Posted - 08/27/24

$TECH ScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine https://www.stocktitan.net/news/TECH/scale-ready-announces-the-inaugural-g-rex-r-grant-has-been-awarded-wroyysvhxck8.html

User Image letsagooo Posted - 3 months ago

$CLNN higher high and higher lows as volume trickles down. Company is hard at work with FDA approval and updates on twitter. Traders will chase. Low float will send CLNN stock price to analyst target prices. Question is, are we stopping at 20, going to 94 or some place in between. Accelerated FDA approval for Q3. Should be seeing something good in the next 30-60 days. Most likely it will be bought out by the big boys but it is a good investment in my opinion. $VRTX $MRNA $TECH $INCY

User Image Thestocktraderhubzee Posted - 3 months ago

WATCHLIST AUG 09 2024 $IGIC RBC Capital Maintains Outperform on Intl General Insurance, Raises Price Target to $19 $ITCI RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $106 $TECH RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $70 $CE RBC Capital Maintains Outperform on Celanese, Lowers Price Target to $167 $CPAY RBC Capital Reiterates Sector Perform on Corpay, Maintains $310 Price Target

User Image Thestocktraderhubzee Posted - 3 months ago

$TECH Baird Maintains Outperform on Bio-Techne, Raises Price Target to $82

User Image epsguid Posted - 3 months ago

$TECH reported earnings of $0.49, consensus was $0.44 via @eWhispers #epsbeat http://eps.sh/d/tech

User Image Stock_Titan Posted - 3 months ago

$TECH BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS https://www.stocktitan.net/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2024-bc163rl9ixc7.html

User Image NVDAMillionaire Posted - 3 months ago

$TECH BIO-TECHNE CORPORATION (NASDAQ:TECH) – A LEADER IN LIFE SCIENCES INNOVATION http://beyondspx.com/2024/08/01/bio-techne-corporation-nasdaqtech-a-leader-in-life-sciences-innovation/

User Image Stock_Titan Posted - 07/31/24

$TECH BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM https://www.stocktitan.net/news/TECH/bio-techne-announces-next-generation-high-throughput-simple-western-qzywqwbjnucl.html

User Image DonCorleone77 Posted - 07/29/24

$TECH Bio-Techne investing in Spear Bio 1Bio-Techne announced its participation in Spear Bio's $45M Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. Bio-Techne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is involved in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. The initial offering will focus on key biomarkers supporting translational research in Alzheimer's disease.

User Image vjtweet Posted - 4 months ago

$TECH at a fantastic buy point.

User Image LewisDaKat Posted - 4 months ago

News Article $TECH Netflix Ends Lowest-Priced Ad-Free Plan In The US: Here Are Your Choices Now | Benzinga https://marketwirenews.com/articles/netflix-ends-lowest-priced-ad-free-plan-in-the-us-he-mwn-benzinga-39852314.html $TECH

User Image Stock_Titan Posted - 4 months ago

$TECH BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS https://www.stocktitan.net/news/TECH/bio-techne-to-host-conference-call-on-august-7-2024-to-announce-9ti1w4mh8xmk.html

Analyst Ratings
Benchmark Buy Aug 13, 24
RBC Capital Sector Perform Aug 8, 24
Baird Outperform Aug 8, 24
Citigroup Neutral May 22, 24
Benchmark Buy May 2, 24
Baird Outperform May 2, 24
Deutsche Bank Buy Apr 18, 24
Stephens & Co. Overweight Feb 2, 24
RBC Capital Sector Perform Feb 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Jul 21 Sell 88.3628 80,000 7,069,024 1,258,766 07/25/23
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Jun 30 Option 26.65 616,676 16,434,415 1,729,493 07/05/23
Kelderman Kim Pres. Diagnostics &.. Pres. Diagnostics & Genom Aug 23 Option 150.78 663 99,967 3,801 08/25/22
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Aug 08 Option 177.32 563 99,831 6,523 08/10/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jul 28 Option 108.49 45,346 4,919,588 262,749 08/01/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jul 06 Option 108.49 50,000 5,424,500 248,338 07/08/22
HIGGINS JOHN L Director Director Jun 07 Option 66.9 1,600 107,040 5,206 06/09/22
HIGGINS JOHN L Director Director Jun 07 Sell 365.2 1,600 584,320 4,606 06/09/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 07 Option 108.49 5,104 553,733 203,442 06/09/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 07 Sell 365 5,104 1,862,960 198,338 06/09/22
BAUMGARTNER ROBERT V Director Director May 10 Buy 352.55 300 105,765 10,106 05/11/22
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 01 Option 125.05 9,022 1,128,201 10,955 11/03/21
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 01 Sell 526.65 9,022 4,751,436 10,755 11/03/21
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Sep 07 Sell 510.25 6,871 3,505,928 7,620 09/07/21
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Sep 07 Option 125.05 6,871 859,219 14,491 09/07/21
BAUMGARTNER ROBERT V Director Director Aug 25 Option 87.39 4,000 349,560 13,612 08/25/21
BAUMGARTNER ROBERT V Director Director Aug 25 Sell 485.27 4,000 1,941,080 9,612 08/25/21
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Jun 16 Sell 449.6 7,481 3,363,458 166,904 06/16/21
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Feb 18 Option 94.35 30,000 2,830,500 176,269 02/18/21
Eansor Norman David President-Protein Sc.. President-Protein Sciences Feb 09 Option 106.59 32,933 3,510,328 34,251 02/09/21
Eansor Norman David President-Protein Sc.. President-Protein Sciences Feb 09 Sell 381.75 32,933 12,572,173 1,318 02/09/21
Hippel James Chief Financial Offi.. Chief Financial Officer Jan 13 Option 106.59 10,000 1,065,900 19,137 01/13/21
Hippel James Chief Financial Offi.. Chief Financial Officer Jan 13 Sell 332.19 10,000 3,321,900 9,137 01/13/21
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Dec 02 Sell 302.1 10,857 3,279,900 6,124 12/02/20
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Dec 02 Option 106.59 11,795 1,257,229 16,981 12/02/20
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 12 Option 106.59 10,991 1,171,531 16,528 11/12/20
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 12 Sell 309.14 10,991 3,397,758 9,137 11/12/20
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Nov 10 Option 86.25 25,157 2,169,791 186,644 11/10/20
STEER RANDOLPH C Director Director Nov 10 Option 68.63 10,000 686,300 15,112 11/10/20
STEER RANDOLPH C Director Director Nov 10 Sell 301.97 10,000 3,019,700 5,112 11/10/20
HIGGINS JOHN L Director Director Nov 10 Option 70.35 5,000 351,750 9,412 11/10/20
HIGGINS JOHN L Director Director Nov 10 Sell 299.96 5,000 1,499,800 4,412 11/10/20
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 06 Option 108.49 15,909 1,725,967 17,946 11/06/20